前列腺素E2受體4(EP4R)抑制劑-開發平台分析:2022年

本報告提供EP4R抑制劑的市場機會的主要的競爭分析，開發平台醫藥品的簡介的企業，臨床試驗，其他的發展趨勢等彙整資料。

樣本圖

目錄

概要

EP4R抑制劑的標的背景

• EP4R(前列腺素E2受體4)-概要
• C-IC的EP4拮抗劑的作用機制
• EP4抑制劑臨床應用

EP4R抑制劑開發平台分析，各相

• EP4R抑制劑的開發- 概要
• 開發中產品，各開發階段
• EP4R抑制劑的競爭情形環境，各相
• 開發中產品，各企業
• 開發中產品，適應症及各相
• EP4R抑制劑臨床及法規單劑療法及聯合治療
• EP4R抑制劑- 適應症/各相資產
• EP4R抑制劑臨床及法規的時間軸

EP4R抑制劑的授權，收購，及聯盟契約

EP4R抑制劑開發平台的展望

• 簡介比較概要
• EP4R抑制劑開發平台的藥物簡介
  • 第二階段
    • CR6086
    • Grapiprant
  • 第一/二階段
    • ONO 4578
    • Grapiprant
  • 第Ib相
    • Palupiprant
    • INV 1120
    • TPST 1495
  • 第一階段
    • KF-0210
    • DT-9081
  • 前臨床
    • AAT-008
    • YY001
    • P001
  • EP4R抑制劑SWOT分析
  • EP4R抑制劑產品的定位
  • 附錄

EP4R Inhibitors report covers the EP4R Inhibitors market opportunity providing Key Competitive Analysis, 16+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partners as well as Clinical Partner. The report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area, and indication by phases. EP4R inhibitor's reports add value in terms of describing clinical stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

SAMPLE VIEW

Given the multiple tumor-promoting roles of EP4 expression on tumor cells and host immune cells and endothelial cells, revealed that the combination of EP4 antagonists and other immunomodulating drugs should work synergistically, especially in TNBCs displaying a diverse microenvironment. This strongly suggests the potential benefit of EP4 antagonists in combination with other immunomodulating agents in cancer therapy.

In this report, Mellalta Meets provides an in-depth analysis of EP4R inhibitors covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 12 candidate EP4R inhibitor products currently under evaluation in clinical and preclinical studies. The major key players operating in the market are Rottapharm Biotech, Haihe Biopharma/3D Medicine, Bristol-Myers Squibb/Ono Pharmaceuticals, Ikena Oncology, and many more which have robust clinical pipelines of EP4R inhibitor candidates.

As per analysis, the EP4 receptor is currently emerging as the most versatile and promising among PGE2 receptors with the development pipeline full of Molecules like small molecules and combination therapies.

Key Highlights of EP4R Inhibitors Report:

• There are ~5 products in the Phase 1 stage of development, representing 41.67% of the total share of the developing EP4R inhibitors landscape. The remaining 58.33% has been contributed by pre-clinical (25%); Phases 2 and 1/2 (16.67%).

• The pipeline of EP4R Inhibitors is dominated by biotech companies headquartered in China with Chinese companies holding the top 6 positions. They represent ~37.50% of all the pipeline EP4R inhibitors in clinical stages.

• EP4R Inhibitors pipeline landscape includes 47% of Monotherapy trials and 53% of Combination Trials

• The pipeline of EP4R inhibitors is dominated by Phase 1 (5); Pre-clinical (3); Phase 2 (2) assets and Phase 1/2 (2) assets.

• To be continued...

Report Coverage:

• Indication Prioritisation: EP4R Inhibitors market potential based on Indications

• Business Transactions & Strategies: Key collaborations and deal values

• EP4R Inhibitors Pipeline Development: Product Profiles, Clinical Trials & Results

• EP4R Inhibitors Acquisition Targets

• EP4R Inhibitors Competitive Intelligence

• Recent & Upcoming events

TABLE OF CONTENTS

OVERVIEW

The EP4R Inhibitors Target BACKGROUND

• EP4R (Prostaglandin E2 Receptor 4) -Overview
• Mechanism of Action of EP4 Antagonist in the C-IC
• Clinical Application of EP4 Inhibitors

EP4R Inhibitors PIPELINE ANALYSIS by Phases

• EP4R Inhibitors Development - Overview
• Pipeline Products by Stage of Development
• EP4R Inhibitors Competitive Landscape by Phases
• Pipeline Products by Company
• Pipeline Products by Indication and Phases
• EP4R Inhibitors Clinical & Regulatory Monotherapy & Combinations
• EP4R Inhibitors- Assets by Indication/Phase
• EP4R Inhibitors Clinical & Regulatory Timelines

EP4R Inhibitors LICENSING, ACQUISITION, AND COLLABORATION DEALS

• EP4R Inhibitors Licensing, Acquisition, and Deal values
• EP4R Inhibitors Licensing by Transaction type and total amount size by Phases

EP4R Inhibitors Pipeline Landscape

• Profile Comparisons At-a-glance
• EP4R Inhibitors Pipeline Drug Profiles
  • Phase II
    • CR6086 (Rottapharm Biotech)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • Grapiprant (Haihe Biopharma/3D Medicine)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
  • Phase I/II
    • ONO 4578 (Bristol-Myers Squibb/ Ono Pharmaceuticals)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • Grapiprant (Ikena Oncology; AskAt; NewBay)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
  • Phase Ib
    • Palupiprant (Adlai Nortye/Eisai Inc)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • INV 1120 (Shenzhen Ionova Life Sciences Co., Ltd.)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • TPST 1495 (Tempest Therapeutics)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
  • Phase I
    • KF-0210 (Keythera Pharmaceuticals)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • DT-9081 (Domain Therapeutics)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
  • Preclinical
    • AAT-008 (Ikena Oncology; AskAt; NewBay)
      • Product Profile & Description
      • Collaborations
      • Other Developments
    • YY001 (Bio Ray Lab)
      • Product Profile & Description
      • Collaborations
      • Other Developments
    • P 001 (NB Health Laboratory)
      • Product Profile & Description
      • Collaborations
      • Other Developments
  • EP4R Inhibitors SWOT Analysis
  • EP4R Inhibitors Products Positioning
  • Appendix
    • About us